Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1996-06-06
2000-10-24
Moezie, F. T.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 17, 530317, 530330, 424 64, 424813, 424814, A61K 3812
Patent
active
061367818
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention provides LH-RH receptor antagonists containing cyclic pentapeptides or salts thereof having an LH-RH receptor antagonistic effect and novel cyclic pentapeptides or salts thereof having an excellent LH-RH receptor antagonistic effect.
2. Description of Related Art
The secretion of anterior pituitary hormones is controlled by peripheral hormones to be secreted by the organs, which are targeted by the individual anterior pituitary hormones, and also by secretion-promoting or secretion-retarding hormones to be secreted by the hypothalamus which is the upper center of the anterior lobe of hypophysis (these hormones are hereinafter referred to as hypothalamus hormones). At present, the presence of nine hypothalamus hormones has been confirmed, which include, for example, thyrotropin releasing hormone (TRH) and gonadotropin releasing hormone (GnRH) [this is also referred to as luteinizing hormone releasing hormone (LH-RH)] (Irie, M. & Toyama, K., Physiology 2, Bunkodo Publishing, pp. 610-618, 1986). It is presumed that these hypothalamus hormones exhibit their hormone effects, etc. via the receptors which are considered to exist in the anterior lobe of hypophysis (ibid.), and the analysis of receptor genes specific to these, including those of human beings, is being promoted (Imura, H. et al.; Bases and Clinics of Receptors, Asakura Shoten Publishing, pp. 297-304, 1993). Therefore, antagonists and agonists which are specific and selective to these receptors shall control the action of hypothalamus hormones and control the secretion of anterior pituitary hormones. As a result, such antagonists and agonists are expected to be useful for prevention and curing of disorders dependent on such anterior pituitary hormones.
The repeated administration of leuprorelin acetate, a highly-active derivative of luteinizing hormone releasing hormone (hereinafter referred to as LH-RH) which is one of hypothalamus hormones (Fujino et al., Biochemical and Biophysical Research Communication, Vol. 60, pp. 406-413, 1975; Oliver, R. T. D., et al., Br. J. Cancer, Vol. 59, p. 823, 1989; and Toguchi, et al., J. Int. Med. Res., Vol. 18, pp. 35-41, 1990) lowers the release and production of luteinizing hormone at hypophysis, lowers the reactivity of testis and ovarium on luteinizing hormone and retards the secretion of testosterone and estrogen. Accordingly, it is known that leuprorelin acetate exhibits anti-tumoral activity against cancers dependent on such hormones, such as prostatic cancer, and it has been applied to clinical use. In addition, leuprorelin acetate has been widely applied to clinical use as a medicine for curing endometriosis, puberty precox, etc. It is presumed that the high carcinostatic activity of leuprorelin acetate will result from the fact that it is more resistant to proteases than natural LH-RH and the fact that it has high affinity with LH-RH receptors thereby causing the desensitization of the reactivity of LH-RH due to the decrease in the number of its receptors. However, since leuprorelin acetate is an super-agonist for LH-RH receptors, it is reported that the acetate causes transient exacerbation that is accompanied by the increase in the serum testosterone concentration, due to its pituitary-gonadotropic effect (acute effect), immediately after the first administration thereof.
Given the background situations as above, LH-RH antagonists are desired which have more excellent curing effect while not exhibiting the above-mentioned transient pituitary-gonadotropic effect (acute effect).
The various cyclic pentapeptides (FEBS LETTERS, vol. 291, No. 1, 50-54 (1991), Biochemical Society Transactions, Current Techniques in Polypeptide Structure and Synthesis, 1049-1052 (1994), U.S. Pat. No. 4,508,711, EP-A 436,189, EP-A 528,312, EP-A 606881, Japanese Patent Laid-Open No. 3-94692, 3-130299, 6-192293, 5-59098 and 5-194589) have been reported. However, they have not disclosed about LH-RH receptor antagonistic effect.
As compounds showing LH-RH
REFERENCES:
patent: 4508711 (1985-04-01), Coy et al.
patent: 5516889 (1996-05-01), Hollenberg et al.
Kessler et al, Liebigs Ann. Chem, 1989 (3) pp. 269-294.
Ehrlich et al, Tetrahedron Lett. (1993) 34(30) p. 4781-4.
Etzkorn, et al, (1994) pp. 10412-10425, J. Am Chem Soc.
Ehrlich et al, Synthesis of Cyclic Peptides via Efficient New Coupling Reagents, Tetrahedron Letters, vol. 34, No. 30, pp. 4781-4784, 1993.
Aumailley et al., "Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1", FEBS LETTERS, vol. 291, No. 1, pp. 50-54, 1991.
"PEPTIDES, Structure and Function", Charles M. Deber, et al., Proceedings of the Ninth American Peptide Symposium, pp. 549-552, 1985.
"Bioactive Conformation of Luteinizing Hormone-Releasing Hormone: Evidence from a Conformationally Constrained Analog", Roger M. Freidinger, et al., SCIENCE, vol. 210, No. 4470, pp. 656-658, 1980.
"A potent cyclic hexapeptide analogue of somatostatin", Daniel F. Veber, et al, NATURE, vol. 292, 2 pp. 55-58, 1981.
Furuya Shuichi
Kato Koichi
Kitada Chieko
Moezie F. T.
Takeda Chemical Industries Ltd.
LandOfFree
LH-RH receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with LH-RH receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and LH-RH receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1964108